Frontiers in pharmacology · 2026
Hesperetin and Naringenin promote glucagon-like peptide-1 secretion from L-cell through activation of TGR5 and alleviated type 2 diabetes.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Chen-Yang, Wang Zi-Lu, Jiang Ze-Ju, Kim Hanna, Liu Chang, Wang Hao
Аннотация
PURPOSE: Glucagon-like peptide-1 (GLP-1) secretagogues offer therapeutic potential for type 2 diabetes. Bioactive compounds in citrus were supposed to be effective in treating diabetes, while exact compounds activating enteroendocrine L-cell pathways remain underexplored. This study aimed to identify citrus-derived compounds that stimulate GLP-1 secretion from L cells by screening a traditional Chinese medicine library and to elucidate the underlying cellular mechanisms.
METHODS: A reporter GLUTag cell line (murine L cell line), designed to introduce a luciferase into the proglucagon sequence, was utilized to screen a traditional Chinese medicine library. The effects of selected compounds on GLP-1 secretion were evaluated in both GLUTag cells and primary mouse ileac epithelial cells. Intracellular cAMP levels and calcium flux were measured to elucidate their underlying mechanism, and a dual-luciferase reporter assay was used to confirm their activation on TGR5 target. In vivo effect was confirmed in high-fat-diet-induced diabetic mice by oral administration.
RESULTS: Hesperetin and Naringenin significantly promoted GLP-1 secretion from L cells. Both compounds increased cAMP accumulation and intracellular calcium influx in L cells, effects that were largely absent in TGR5-deficient L cells. Subsequently, dual-luciferase reporter assays identified them as TGR5 activators. Furthermore, cellular thermal shift assay (CETSA) provided evidence that each flavonoid forms a stable complex with TGR5. Finally, in high-fat-diet-induced diabetic mice, oral administration of either compound enhanced glucose-stimulated serum GLP-1 levels and ameliorated obesity and hyperglycemia under obese diabetic conditions.
CONCLUSION: This study demonstrated that Hesperetin and Naringenin promoted GLP-1 secretion from L-cells through TGR5 activation and alleviated type 2 diabetes.
METHODS: A reporter GLUTag cell line (murine L cell line), designed to introduce a luciferase into the proglucagon sequence, was utilized to screen a traditional Chinese medicine library. The effects of selected compounds on GLP-1 secretion were evaluated in both GLUTag cells and primary mouse ileac epithelial cells. Intracellular cAMP levels and calcium flux were measured to elucidate their underlying mechanism, and a dual-luciferase reporter assay was used to confirm their activation on TGR5 target. In vivo effect was confirmed in high-fat-diet-induced diabetic mice by oral administration.
RESULTS: Hesperetin and Naringenin significantly promoted GLP-1 secretion from L cells. Both compounds increased cAMP accumulation and intracellular calcium influx in L cells, effects that were largely absent in TGR5-deficient L cells. Subsequently, dual-luciferase reporter assays identified them as TGR5 activators. Furthermore, cellular thermal shift assay (CETSA) provided evidence that each flavonoid forms a stable complex with TGR5. Finally, in high-fat-diet-induced diabetic mice, oral administration of either compound enhanced glucose-stimulated serum GLP-1 levels and ameliorated obesity and hyperglycemia under obese diabetic conditions.
CONCLUSION: This study demonstrated that Hesperetin and Naringenin promoted GLP-1 secretion from L-cells through TGR5 activation and alleviated type 2 diabetes.